bupivacaine hydrochloride · Fresenius Kabi Usa · NDA 018304
Sensorcaine
Earliest generic entry, as listed · earliest of 5 marketed strengths
Open now
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 25 Oct 2026Generic approved · 018304-00122 Apr 2026
Products covered · 5
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 018304 · 001 · RLD | injectable, injection | 0.25% | open |
| 018304 · 002 · RLD | injectable, injection | 0.5% | open |
| 018304 · 003 · RLD | injectable, injection | 0.75% | open |
| 018304 · 004 · RLD | injectable, injection | 0.5%;0.0091MG/ML | open |
| 018304 · 005 · RLD | injectable, injection | 0.75%;0.0091MG/ML | open |